Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) | MicrobiomeTrials← Back to trialsNCT07045909
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-06-30Est. Completion: 2028-03-31
Enrollment target: 30 participants Locations- Hospital Germans Trias i Pujol (ICO BADALONA), Badalona, Spain
- H. Clinic de Barcelona, Barcelona, Spain
- H. 12 de Octubre, Madrid, Spain
- H. Ramón y Cajal, Madrid, Spain
- Clinica Universidad de Navarra, Pamplona, Spain
- Hospital Clinico Universitario Salamanca, Salamanca, Spain
- H. Marqués de Valdecilla, Santander, Spain
- C H Santiago de Compostela, Santiago de Compostela, Spain
- Complejo Hosp. Regional Virgen del Rocío, Seville, Spain
- Hospital Universitario y Politécnico La Fe de Valencia, Valencia, Spain
Other microbiome trials you might be interested in
Multiple Myeloma
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab…
Mobile, United StatesEst. completion Aug 30, 2026
Relapse Multiple Myeloma
The goal of this retrospective observational study is to characterize multiple myeloma (MM) patients (by collecting demo…
Multiple LocationsEst. completion Dec 31, 2027
Recruiting
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaMultiple Myeloma ProgressionMultiple Myeloma Refractory
Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatmen…
Copenhagen, DenmarkEst. completion Jun 30, 2027